Correlation Between SAB Biotherapeutics and Actinium Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both SAB Biotherapeutics and Actinium Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SAB Biotherapeutics and Actinium Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between SAB Biotherapeutics and Actinium Pharmaceuticals, you can compare the effects of market volatilities on SAB Biotherapeutics and Actinium Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SAB Biotherapeutics with a short position of Actinium Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of SAB Biotherapeutics and Actinium Pharmaceuticals.

Diversification Opportunities for SAB Biotherapeutics and Actinium Pharmaceuticals

-0.44

Correlation Coefficient

SAB Biotherapeutics  Actinium Pharmaceuticals

Very good diversification

The 3 months correlation between SAB and Actinium is -0.44. Overlapping area represents the amount of risk that can be diversified away by holding SAB Biotherapeutics and Actinium Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Actinium Pharmaceuticals and SAB Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SAB Biotherapeutics are associated (or correlated) with Actinium Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Actinium Pharmaceuticals has no effect on the direction of SAB Biotherapeutics i.e., SAB Biotherapeutics and Actinium Pharmaceuticals go up and down completely randomly.

Pair Corralation between SAB Biotherapeutics and Actinium Pharmaceuticals

Assuming the 90 days horizon SAB Biotherapeutics is expected to generate 4.08 times more return on investment than Actinium Pharmaceuticals. However, SAB Biotherapeutics is 4.08 times more volatile than Actinium Pharmaceuticals. It trades about 0.18 of its potential returns per unit of risk. Actinium Pharmaceuticals is currently generating about -0.12 per unit of risk. If you would invest  2.50  in SAB Biotherapeutics on September 12, 2024 and sell it today you would earn a total of  4.50  from holding SAB Biotherapeutics or generate 180.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	88.89%
Values	Daily Returns

SAB Biotherapeutics  vs.  Actinium Pharmaceuticals

SAB Biotherapeutics

Risk-Adjusted Performance

14 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in SAB Biotherapeutics are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, SAB Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Actinium Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Actinium Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with SAB Biotherapeutics and Actinium Pharmaceuticals

The main advantage of trading using opposite SAB Biotherapeutics and Actinium Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SAB Biotherapeutics position performs unexpectedly, Actinium Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Actinium Pharmaceuticals will offset losses from the drop in Actinium Pharmaceuticals' long position.

The idea behind SAB Biotherapeutics and Actinium Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.